Portfolio Manager David Peltier highlights TherapeuticsMD (TXMD) as one of his top stocks under $10 for 2015. The stock fell 27% in 2014, but the biotech firm has an attractive clinical pipeline of potential female hormone replacement therapies with multiple potential catalysts. The company's two lead products are currently in Phase 3 studies. While potential approval from the Food and Drug Administration is still a year or two away, TherapetuicsMD can still deliver several newsworthy milestones in 2015. Peltier believes the stock can trade back up toward the high-single digits in the new year.
Scroll to Continue